Brief Report: Should Abacavir Be a First-Line Alternative for Adults with HIV in Sub-Saharan Africa?

Guinevere Q. Lee, Suzanne McCluskey, Yap Boum, Peter W. Hunt, Jeffrey N. Martin, David R. Bangsberg, Xiaojiang Gao, P. Richard Harrigan, Jessica E. Haberer, Mark J. Siedner

Research output: Contribution to journalArticlepeer-review

Abstract

Despite a poor toxicity profile, zidovudine supersedes abacavir (ABC) as an alternative first-line agent in most international treatment guidelines because of concerns about HLA-B57:01-related ABC-hypersensitivity. We detected one case of HLA-B57:01 carriage among 513 HIV-infected individuals in Uganda, which, in combination with previous reports, supports the safety of ABC in the region.

Original languageEnglish (US)
Pages (from-to)188-192
Number of pages5
JournalJournal of Acquired Immune Deficiency Syndromes
Volume76
Issue number2
DOIs
StatePublished - Oct 1 2017

Keywords

  • Africa
  • HIV
  • HLA-B57:01
  • Uganda
  • abacavir
  • antiretroviral therapy

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Brief Report: Should Abacavir Be a First-Line Alternative for Adults with HIV in Sub-Saharan Africa?'. Together they form a unique fingerprint.

Cite this